Summit: Ivonescimab gets second NMPA approval in China; OS hazard ratio 0.777

Summit Therapeutics Inc.

NMPA approved ivonescimab for front-line PD-L1+ advanced NSCLC based on HARMONi-2 Phase III trial.
Interim OS analysis showed hazard ratio 0.777 (22% reduction in risk of death) at 39% data maturity.
Primary endpoint PFS previously showed HR 0.51 (p<0.0001) favoring ivonescimab over pembrolizumab.
Summit is enrolling HARMONi-7, a multiregional Phase III trial of ivonescimab vs pembrolizumab in same population.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.